APC/Fire™ 750 anti-mouse/human CD11b

Antibodies Single
Sony
M1/70
Flow Cytometry
Rat IgG2b, κ
Human,Mouse,Non-human primate,Other
C57BL/10 splenocytes
1106310
$273.00

Description

CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum emission of 787 nm.

References

  1. Springer T, et al. 1978. Eur. J. Immunol. 8:539. (IP)
  2. Ault K and Springer T. 1981. J. Immunol. 126:359. (Deplete)
  3. Springer TA, et al. 1982. Immunol. Rev. 68:171. (Block)
  4. Ho MK and Springer TA. 1983. J. Biol. Chem. 258:2766. (IP)
  5. Flotte TJ, et al. 1983. Am. J. Pathol. 111:112. (IHC)
  6. Noel GJ, et al. 1990. J. Clin. Invest. 85:208. (IF)
  7. Allen LA and Aderem A. 1996. J. Exp. Med. 184:627 (IF)
  8. D'Amico A and Wu L. 2003. J. Exp. Med. 198:293. (Deplete)
  9. Brickson SJ, et al. 2003. Appl Physiol. 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. J. Exp. Med. 199:717. (IF)
  11. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  12. Zhang Y, et al. 2002. J. Immunol. 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. J. Immunol. 166:4884 (IHC, FC)
  14. Tailleux L. 2003. J. Exp. Med. 197:121. (Block, FC)
  15. Olver S, et al. 2006. Cancer Research 66:571. (FC)
  16. Tan SL, et al. 2006. J. Immunol. 176:2872. (FC) PubMed
  17. Ponomarev ED, et al. 2006. J. Immunol. 176:1402. (FC)
  18. Dzhagalov I, et al. 2007. Blood 109:1620. (FC)
  19. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  20. Rasmussen JW, et al. 2006. Infect. Immun.74:6590. PubMed
  21. Napimoga MH, et al. 2008. J. Immunol. 180:609. PubMed
  22. Elqaraz-Carmon V, et al. 2008. J. Lipid. Res. 49:1894. PubMed
  23. Kim DD, et al. 2008. Blood 112:1109. PubMed
  24. Guo Y, et al. 2008. Blood 112:480. PubMed
  25. Norian LA, et al. 2009. Cancer Res. 69:3086. (FC) PubMed
  26. Baumgartner CK, et al. 2010. J. Immunol. 184:573. PubMed
  27. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  28. Whiteland J, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
  29. Weber GF, et al. 2014. J Exp Med. 211:1243. PubMed
  30. Ashok A, et al. 2015. Toxicol Sci. 143:64. PubMed
  31. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  32. Doni A, et al. 2015. J Exp Med. 212:905. PubMed
  33. Ferreira R, et al. 2016. J Infect Dis. 213: 669 - 673. PubMed
  34. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)